Cancer Research

The landscape of biopharmaceutical research and development (R&D) has seen a remarkable evolution, particularly in the realm of oncology. In recent years, a significant portion of R&D investments has been channeled into cancer research, paving the way for groundbreaking treatments and

Genentech, a prominent subsidiary of Roche, is undergoing significant layoffs and restructuring efforts, which are slated to impact various roles at its South San Francisco operations. This development follows a recent announcement that 93 employees will be laid off starting in early October. The

Recent research breakthroughs have revealed an intriguing and unexpected benefit of certain cancer drugs: the potential to protect against Alzheimer's disease. Originally developed for combating cancer, these medications have shown promise in preventing Alzheimer's in animal models such

The European Commission's recent authorization of Regeneron's bispecific antibody drug Ordspono (odronextamab) for the treatment of two types of lymphoma marks a significant milestone in the European market. Garnering approval for use across 27 European Union countries, Ordspono is now

Sutro Biopharma has announced a significant step forward in the fight against lung cancer by initiating a global Phase 2 clinical trial, aptly named REFRαME-L1, for their innovative drug luveltamab tazevibulin (luvelta). This trial aims to evaluate the safety and efficacy of luvelta in adults with

The journey of developing groundbreaking cancer therapies is fraught with challenges and triumphs, and the clinical trial of BNT326/YL202 by BioNTech and MediLink Therapeutics is no exception. This antibody-drug conjugate (ADC) candidate has shown promise in treating non-small cell lung cancer and